Sugentech수젠텍
253840 · KOSDAQ · ₩253840 · 수젠텍
- Market cap
- ₩67B
- Enterprise value
- ₩51B
- P/E
- —
- P/B
- 1.0×
- Dividend yield
- 0.0%
- ROE
- −33.7%
- Net margin
- −235.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−51.2% from the high
₩3,530Today: ₩4,030 – ₩4,220₩8,250
Returns
- 1W−9.1%
- 1M−11.7%
- 3M+0.8%
- 6M−28.5%
- YTD−34.4%
- 1Y−40.0%
- Volume today
- 62,538
- 0.2× the 20-day average
- Traded today
- ₩256M
- Listed shares
- 16,743,200
- EPS (12 months)
- −₩1,374
- Earnings yield −34.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-10.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Sugentech stock overview
Sugentech (수젠텍, KRX: 253840) is listed on KOSDAQ, in the Biotech & Pharma sector. Suzentech develops, manufactures and commercializes diagnostic technologies and products that combine bio, nano, IT and AI technologies, across multiplex immunoblot lab tests for hospitals and testing laboratories, point-of-care tests for clinics, and digital home-test healthcare products. Its shares closed at ₩4,030 on Oct 26, 2026, down 3.82% on the day, giving it a market value of ₩67B.
Key facts
- Market cap
- ₩67B
- Sector
- Biotech & Pharma
- Latest price change
- −3.82%
- As of
- Oct 26, 2026
- Main business
- Suzentech develops, manufactures and commercializes diagnostic technologies and products that combine bio, nano, IT and AI technologies, across multiplex immunoblot lab tests for hospitals and testing laboratories, point-of-care tests for clinics, and digital home-test healthcare products.
Quick answers about Sugentech
- What does Sugentech do?
- Suzentech develops, manufactures and commercializes diagnostic technologies and products that combine bio, nano, IT and AI technologies, across multiplex immunoblot lab tests for hospitals and testing laboratories, point-of-care tests for clinics, and digital home-test healthcare products. The company is also expanding into health and beauty, including dietary supplements and cosmetics based on diagnostic data, and it operates in Korea and globally.
- What is the market cap of Sugentech?
- The market capitalisation of Sugentech was ₩67B at the close on Oct 26, 2026.
- Who are the largest shareholders of Sugentech?
- According to the latest official filings, the largest reported holders are Son Mi-jin (14.82%, as of Jan 21, 2025); Kim Eun-kyung (0.58%, as of Apr 8, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.19%, as of Jul 31, 2026).
- When is the next earnings report from Sugentech?
- Korean companies rarely announce results dates in advance. Based on when Sugentech filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Suzentech develops, manufactures and commercializes diagnostic technologies and products that combine bio, nano, IT and AI technologies, across multiplex immunoblot lab tests for hospitals and testing laboratories, point-of-care tests for clinics, and digital home-test healthcare products. The company is also expanding into health and beauty, including dietary supplements and cosmetics based on diagnostic data, and it operates in Korea and globally.
Written by AI from the company's latest annual report.
- Korean name
- 수젠텍
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 손미진
- Founded
- Dec 2011
- Listed
- May 2019
- Listed shares
- 16,743,200
- Fiscal year ends
- Month 12
- Website
- www.sugentech.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 20, 2026
- Insider shareholding reportJul 20, 2026
- Notice on Grant of Stock Purchase OptionsMay 27, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Sugentech / 수젠텍 / 253840 / KRX:253840
Source: KRX statistical information